Braxia Scientific offers new audio webcast and new dial-in number for Annual General Meeting

TORONTO, October 27, 2021 / PRNewswire / – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for people with depression and Related troubles, provides revised details today as part of its annual general meeting of shareholders to be held on 28 October 2021, To 10:00 a.m. (ET). The Company informs that the audio webcast and the telephone number for shareholders who wish to listen to the meeting have been modified from those provided in the notice of meeting of the annual general meeting and the circular of Company information. The updated audio webcast and call number are below:

Audio webcast link: https://blgmeet.webex.com/blgmeet/j.php?MTID=m750ffdfddefd39728bc2826e26adce36

Meeting number: 2345 825 5938

Password: appointment 2021

Phone number: + 1-844-974-2903

Access code: 234 582 55938

Further details of the Meeting are included in the Notice of Annual General Meeting and Information Circular on the Company’s website and available at www.sedar.com.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for people with depression and related disorders. Through its medical solutions, Braxia aims to reduce the disease burden of brain-related mental disorders such as major depressive disorder, among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, treatment of mental health disorders, and (ii) research activities related to the discovery and commercialization of new drugs and delivery methods. . Braxia is looking to develop ketamine and derivatives and other psychedelics from its IP development platform. Through its wholly owned subsidiary, the Canadian Center of Excellence for Rapid Treatment Inc., Braxia currently operates multidisciplinary community clinics providing rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

ON BEHALF OF THE BOARD

“Dr. Roger S. McIntyre
Dr. Roger S. McIntyre

Chairman and CEO

Website: www.braxiascientific.com

The CSE has not reviewed and accepts no responsibility for the accuracy or relevance of this release.

Caution regarding forward-looking information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”.

Forward-looking statements include statements about the promise of ketamine-based treatments for depression and the potential of ketamine to treat other emerging psychiatric disorders, such as bipolar depression. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from the future results, events or developments expressed or implied by such forward-looking statements. These risks and uncertainties include, among others, the inability of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unintended side effects, addiction to obtaining and maintaining approvals regulatory authorities, including the acquisition and renewal of federal, provincial, municipal, local or other authorities. licenses and engage in activities that may later be deemed illegal under national or international law. Ketamine and psilocybin are currently scheduled substances in Schedule I and Schedule III, respectively, under the Controlled Drugs and Substances Act, SC 1996, c. 19 (the “CDSA”) and possession of such substances under the CDSA without a prescription or statutory exemption constitutes a criminal offense. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally licensed drug for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription. These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements. Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actual actions to differ from those described in forward-looking statements. actions, events or results differ from those anticipated, estimated or predicted. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

SOURCE Braxia Scientific Corp.

Related links

www.braxiascientific.com


Source link

Comments are closed.